Successful diabetes collab adds new product to lineup

28 January 2020

Diabetes triplet medicine Trijardy (empagliflozin/linagliptin/metformin) has won approval from the US regulator as a therapy, along with diet and exercise, to lower blood sugar levels for adults with diabetes.

Developed by German private firm Boehringer Ingelheim and Eli Lilly (NYSE: LLY), Trijardy is the result of a long-standing alliance in diabetes, which the firms updated in 2014.

The product provides three type 2 diabetes medicines in one pill, including Boehringer and Lilly’s Jardiance (empagliflozin) and Tradjenta (linagliptin), together with metformin hydrochloride.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK